Surgery Partners, Inc. SGRY

Shares of Surgery Partners jumped 15.7% to $15.8 on robust volume after completing the sale of its Idaho Falls facilities interests to Intermountain Health for $797 million gross ($587 million net cash at closing, subject to post-closing adjustments). The deal boosts liquidity and shifts the asset base as the company awaits its next report. For the upcoming quarter, the company is expected to post $0.09 per share, down about 30.8% year over year, with revenues projected at $856.73 million, up 4.3% from a year ago. Earnings estimate revisions have risen about 40% in the last 30 days, a trend that can lift near-term sentiment. The stock carries a Zacks Rank #3 (Hold) in the Medical Services industry. Large cash proceeds from Idaho Falls sale and upbeat earnings revision signal meaningful near-term liquidity and sentiment boost.

Shares of Surgery Partners (SGRY) sit at $15.67, up about 30.8% in six months, outpacing the S&P 500 by roughly 12.8% on a rebound that followed solid Q2 results. Despite the run, equity researchers remain cautious. They flag waning demand with unit sales barely growing 3% year over year for the past two years, and they forecast revenue to fall about 3.4% in the next 12 months after stronger five-year growth of 9.9% annually. The balance sheet adds risk: $3.83 billion in debt dwarfs only $216.7 million in cash, yielding a net-debt-to-EBITDA of about 7x, implying higher borrowing costs and potential rating downgrades if profits falter. The stock trades around 53.9x forward earnings, pricing in good news. The conclusion: not a top pick here; stronger opportunities are suggested elsewhere, with emphasis on other names favored by the analysts. High debt levels and a projected revenue decline pose moderate downside risk to profitability and valuations.

Surgery Partners (SGRY) beat Q2 earnings expectations, with the stock potentially undervalued based on results. Q2 earnings beat signals positive financial results that may support moderate stock revaluation.

Surgery Partners (SGRY) released its Q2 2026 earnings call transcript covering financial results, operational updates, and forward guidance. Quarterly earnings data can shift near-term sentiment and valuation but rarely redefine long-term competitive position.

Surgery Partners held its Q2 earnings call featuring five top analyst questions on financial results, operational performance, and strategic outlook. Earnings call questions often surface investor concerns that moderately affect near-term stock sentiment and operational focus.

Surgery Partners (SGRY) ranks as one of Wall Street’s preferred stocks for further research while two other stocks are flagged to avoid. Analyst endorsement of SGRY as a stock worth deeper review can lift near-term investor sentiment and trading activity.

Surgery Partners Q2 results show portfolio optimization and acuity mix shifts driving operating performance changes. Portfolio optimization and acuity mix adjustments signal moderate operational shifts likely to influence near-term performance without major trajectory changes.

Surgery Partners (SGRY) prepares to report Q2 earnings with focus on revenue, procedure volumes, and cost controls in the outpatient surgery sector. Q2 earnings expectations can moderately sway short-term investor views and valuation for Surgery Partners.

Surgery Partners reported Q2 revenue growth, adjusted EBITDA gains, and updated guidance amid operational improvements and expansion efforts. Q2 earnings updates moderately affect financial outlook and short-term investor sentiment without altering long-term strategy.

Surgery Partners (SGRY) beat Q2 earnings and revenue estimates. Q2 earnings and revenue beats signal stronger financial performance likely to lift near-term investor sentiment.

Surgery Partners exceeded Q2 CY2026 sales expectations. Quarterly sales beats can lift near-term stock sentiment without altering long-term company trajectory.

Surgery Partners reported Q1 earnings placed in context with other outpatient and specialty care stocks. Q1 earnings release offers moderate insight into financial results and sector positioning.

Analysts raised five revealing questions during Surgery Partners' Q1 earnings call, probing growth strategies, surgical volumes, reimbursement pressures, acquisition impacts, and debt management. Revealing analyst questions on Q1 earnings call spotlight financial and operational challenges that could moderately sway investor views on Surgery Partners' trajectory.

Surgery Partners (SGRY) exceeded Q1 expectations and reaffirmed its 2026 outlook, prompting analysis on whether this shifts the investment thesis amid strong growth in surgical facilities and positive market dynamics. Q1 earnings beat and reaffirmed 2026 outlook demonstrate robust performance and long-term confidence, likely boosting investor sentiment and stock trajectory significantly.

Surgery Partners released Q1 earnings call highlights covering financial results, operational performance, growth strategies, and forward-looking guidance. Q1 earnings highlights disclose quarterly financials, revenue growth, and guidance that significantly shape investor expectations and stock trajectory.

Surgery Partners, Inc. (SGRY) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses key financial metrics, growth strategies, and outlook that significantly shape SGRY's trajectory and market valuation.

Surgery Partners, Inc. (NASDAQ:SGRY) Q1 CY2026 sales exceeded analyst estimates. Q1 CY2026 sales beat signals strong financial performance likely to enhance investor sentiment and stock trajectory.

Surgery Partners, Inc. announced first quarter 2026 results and reaffirmed full-year 2026 guidance. Q1 earnings beat or met expectations with reaffirmed full-year guidance, signaling strong operational performance and boosting investor sentiment.

Surgery Partners (SGRY) reported a first-quarter net loss of $0.47 per share but topped revenue estimates with $402.8 million, up 14% year-over-year, amid growth in surgical facilities. Q1 loss despite revenue beat affects short-term financial perception and stock sentiment without altering long-term trajectory.

Surgery Partners (SGRY) Q1 results overview delivers key metrics, growth highlights, and investor insights ahead of the official earnings release. Q1 earnings preview influences financial expectations and short-term market sentiment without fundamentally altering long-term trajectory.

Surgery Partners (SGRY) faces doubts on its margin repair strategy after cutting guidance amid payer mix pressures. Guidance cut and payer mix pressures indicate significant risks to margins and financial trajectory.

Surgery Partners (SGRY) grapples with softer procedure volumes and rising leverage, challenging its anticipated 2026 reset narrative amid concerns over financial health and growth trajectory. Softer volumes erode revenue and higher leverage amplifies debt risks, significantly threatening SGRY's 2026 reset and long-term performance.

Surgery Partners (SGRY) stock plunged 9.7% after releasing a soft 2026 outlook and announcing a new share buyback plan, raising questions about whether the bull case remains intact. Soft 2026 outlook triggered 9.7% stock drop, significantly impacting investor sentiment and future trajectory despite buyback announcement.

Ortelius Capital targets governance shortcomings at Surgery Partners Inc. (SGRY) while its shares screen as undervalued, positioning for potential activist-driven changes. Activist investor Ortelius challenging governance amid undervalued shares could spur major reforms and reshape SGRY's market trajectory.

Ortelius Capital Advisors delivered an open letter to Surgery Partners, Inc. (SGRY) stockholders, outlining concerns and recommendations on strategy, governance, and shareholder value. Activist investor Ortelius's open letter pressures Surgery Partners on strategic changes and governance, potentially shifting investor sentiment and company trajectory.

Ziegler advised Preferred Vascular Group on its acquisition by Surgery Partners, Inc. (SGRY). Acquisition of Preferred Vascular Group expands Surgery Partners' ambulatory surgery network into vascular services.

Surgery Partners released Q4 earnings call highlights, covering financial results, operational updates, strategic initiatives, and forward guidance for the ambulatory surgery center operator. Q4 earnings highlights reveal financial performance and guidance directly influencing stock trajectory and investor sentiment.

Surgery Partners, Inc. released Q4 2025 earnings call summary detailing financial results, operational performance, growth strategies, and future outlook. Q4 earnings call summary discloses financial metrics, guidance, and strategies directly influencing SGRY's trajectory and market sentiment.

Surgery Partners Inc (SGRY) Q4 2025 earnings call highlighted revenue growth despite persistent margin pressures. Revenue growth bolsters financial performance while margin pressures introduce moderate headwinds to profitability.

Surgery Partners (SGRY) reported Q4 earnings that missed analyst estimates, with adjusted EPS of $0.47 versus $0.57 expected and revenue of $405 million falling short of $415.9 million forecast. Missing Q4 earnings estimates highlights weaker financial performance, likely pressuring short-term stock price and investor confidence without fundamentally altering long-term trajectory.